Société de Therapeutique Marocaine S.A. (CBSE:SOT)
Morocco · Delayed Price · Currency is MAD 380.00
+2.00 (0.53%)
At close: Jun 5, 2026
CBSE:SOT Income Statement
Financials in millions MAD. Fiscal year is January - December.
Millions MAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,226 | 2,816 | 2,486 | 2,302 | 2,056 |
| 3,226 | 2,816 | 2,486 | 2,302 | 2,056 | |
Revenue Growth (YoY) | 14.55% | 13.27% | 8.00% | 11.96% | 14.35% |
Cost of Revenue | 1,676 | 1,488 | 1,335 | 1,203 | 1,035 |
Gross Profit | 1,549 | 1,328 | 1,151 | 1,099 | 1,021 |
Selling, General & Admin | 791.49 | 730.61 | 683.37 | 604.7 | 542.4 |
Other Operating Expenses | -35.84 | -31.45 | 17.99 | -45.83 | -35.86 |
Operating Expenses | 821.89 | 767.12 | 756 | 616.05 | 561.16 |
Operating Income | 727.36 | 560.67 | 394.96 | 482.66 | 459.41 |
Interest Expense | -23.46 | -31.21 | -20.36 | -10.03 | -9.11 |
Interest & Investment Income | 0.48 | 0.64 | 0.47 | 0.46 | 0.38 |
Earnings From Equity Investments | -1.36 | -0.64 | -0.33 | -0.02 | -0.12 |
Currency Exchange Gain (Loss) | 21.53 | 11.43 | 18.29 | 3.98 | 2.86 |
Other Non Operating Income (Expenses) | -2.14 | -4.02 | 0.98 | 2.48 | -0.07 |
EBT Excluding Unusual Items | 722.42 | 536.86 | 394.01 | 479.54 | 453.35 |
Gain (Loss) on Sale of Investments | 0.16 | 13.17 | - | -6.54 | - |
Gain (Loss) on Sale of Assets | 0.01 | -0.07 | 73.34 | 0 | 0.03 |
Asset Writedown | -67.55 | -30.88 | -31.7 | -27.95 | -32.79 |
Other Unusual Items | -31.06 | -26.38 | -48.06 | -28.13 | -13.17 |
Pretax Income | 623.99 | 492.71 | 387.6 | 416.92 | 407.42 |
Income Tax Expense | 235.76 | 175.48 | 123.85 | 149.79 | 132.48 |
Earnings From Continuing Operations | 388.23 | 317.22 | 263.75 | 267.13 | 274.95 |
Minority Interest in Earnings | -2.7 | -1.94 | -0.99 | -0.52 | 3.9 |
Net Income | 385.53 | 315.29 | 262.76 | 266.62 | 278.85 |
Net Income to Common | 385.53 | 315.29 | 262.76 | 266.62 | 278.85 |
Net Income Growth | 22.28% | 19.99% | -1.45% | -4.39% | 21.13% |
Shares Outstanding (Basic) | 38 | 36 | 36 | 36 | 36 |
Shares Outstanding (Diluted) | 38 | 36 | 36 | 36 | 36 |
Shares Change (YoY) | 5.65% | - | - | - | - |
EPS (Basic) | 10.14 | 8.76 | 7.30 | 7.41 | 7.75 |
EPS (Diluted) | 10.14 | 8.76 | 7.30 | 7.40 | 7.74 |
EPS Growth | 15.74% | 19.99% | -1.37% | -4.39% | 21.04% |
Free Cash Flow | 382.42 | 120.94 | -17.72 | 86.33 | 265.13 |
Free Cash Flow Per Share | 10.05 | 3.36 | -0.49 | 2.40 | 7.37 |
Dividend Per Share | 6.600 | 5.600 | 3.400 | 5.000 | 5.000 |
Dividend Growth | 17.86% | 64.71% | -32.00% | - | 376.19% |
Gross Margin | 48.03% | 47.15% | 46.30% | 47.73% | 49.64% |
Operating Margin | 22.55% | 19.91% | 15.89% | 20.97% | 22.35% |
Profit Margin | 11.95% | 11.20% | 10.57% | 11.58% | 13.56% |
Free Cash Flow Margin | 11.86% | 4.29% | -0.71% | 3.75% | 12.90% |
EBITDA | 767.76 | 628.62 | 449.6 | 539.84 | 514.04 |
EBITDA Margin | 23.80% | 22.32% | 18.09% | 23.45% | 25.00% |
D&A For EBITDA | 40.4 | 67.96 | 54.64 | 57.18 | 54.63 |
EBIT | 727.36 | 560.67 | 394.96 | 482.66 | 459.41 |
EBIT Margin | 22.55% | 19.91% | 15.89% | 20.97% | 22.35% |
Effective Tax Rate | 37.78% | 35.62% | 31.95% | 35.93% | 32.52% |
Advertising Expenses | 68.93 | 53.82 | 55.26 | 52.09 | 45.89 |